Health Condition 1: null- Daibetes mellitus with peripheral neuropathic pain
Conditions
Interventions
Intervention1: Gabapentin: Group I patients will be put on Gabapentin at a dose of 300 mg HS orally and subsequent therapeutic response along with any adverse drug reactions (ADRs) observed in patient
Sponsors
Government Medical College Patiala
Eligibility
Inclusion criteria
Inclusion criteria: Patients with established diagnosis of type 2 Daibetes mellitus, clinically relevant Diabetic peripheral neuropathic pain, Patients willing to sign informed consent form
Exclusion criteria
Exclusion criteria: Patients already on treatment of neuropathy of different cause, presence of renal, hepatic or cardiovascular insufficiency, patients with epilepsy, uncontrolled hypertension and substance abuse, current/previous diagnosis of psychiatric disorder, pregnant and lactating females, patients taking such drugs for any other disease which are known to cause drug interactions with amitriptyline or gabapentin, patients taking drugs which can cause neuropathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study and compare the effect of Gabapentin and Amitriptyline on improvement of nerve conduction in subjects of type 2 DM with peripheral neuropathic pain- Nerve conduction studyTimepoint: 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To study and compare the efficacy and safety of Gabapentin vs Amitriptyline- Michigan neuropathy screening instrument, visual analog scale and adverse drug reactionsTimepoint: 4 months | — |
Countries
India
Contacts
Public ContactRajneet Kaur
GMC, Patiala
Outcome results
None listed